from TetraKit Technologies
May 20, 2023
We are delighted to announce that our distinguished Chief Scientific Officer, Dr. Matthias Herth, will attend the 25th International Society for Radiopharmaceutical Sciences (ISRS) conference in beautiful Hawaii.
The ISRS conference, renowned for fostering innovation and collaboration, is an ideal platform for presenting our pioneering work and engaging with fellow industry thought leaders. We eagerly anticipate the exchange of ideas that will occur and the partnerships that could potentially evolve from this assembly of bright minds.
Here’s to pushing boundaries toward a brighter, healthier future.
Read more
May 10, 2023
Our COO, Umberto Maria Battisti, will attend the 23rd annual @BioEquity conference in Dublin, Ireland! Umberto’s participation in BioEquity Europe 2023 highlights our commitment to innovation and growth. During the conference, he will seek new partnerships, discuss the latest advancements in biotechnology, and share insights into our company’s strategy for sustained success. We invite you to celebrate Umberto’s journey to Dublin with us, and stay tuned for updates on his experience at this prestigious event. Together, let’s pave the way for a brighter future in biotech!
Read more
May 8, 2023
We’re excited to announce that TetraKit will attend the 2nd Annual Global Meeting COST NOAR Astatine in Coimbra, Portugal, from May 9-11, 2023! This event will bring together academics and industry experts to discuss the latest developments in targeted alpha therapy using astatine-211. Our CEO, Andreas Ingemann Jensen, and CSO, Matthias Herth, represent TetraKit at this global conference. They look forward to engaging in productive conversations, exchanging ideas, and learning from the invited speakers. We’re thrilled to network with fellow professionals and contribute to the progress in this innovative field.
We’ll see you in Coimbra!
#NOAR2023 #TargetedAlphaTherapy #Astatine211 #TetraKit #Coimbra #Portugal #Networking #Innovation #Research
Chief Executive Officer
“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”
Chief Scientific Officer
“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”
© 2022 TetraKit Technologies. All rights reserved
Privacy Policy
